Centaurus Financial’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $130K | Sell |
2,475
-37
| -1% | -$1.96K | 0.01% | 1014 |
|
|
2026
Q1 | $139K | Buy |
2,512
+6
| +0.2% | +$325 | 0.01% | 937 |
|
|
2025
Q4 | $123K | Sell |
2,506
-6,943
| -73% | -$324K | 0.01% | 964 |
|
|
2025
Q3 | $408K | Buy |
9,449
+6,355
| +205% | +$248K | 0.02% | 579 |
|
|
2025
Q2 | $119K | Sell |
3,094
-137
| -4% | -$5.24K | 0.01% | 891 |
|
|
2025
Q1 | $125K | Sell |
3,231
-919
| -22% | -$33.6K | 0.01% | 823 |
|
|
2024
Q4 | $140K | Sell |
4,150
-111
| -3% | -$4K | 0.01% | 775 |
|
|
2024
Q3 | $174K | Sell |
4,261
-254
| -6% | -$10.4K | 0.01% | 674 |
|
|
2024
Q2 | $174K | Sell |
4,515
-1,830
| -29% | -$77K | 0.01% | 637 |
|
|
2024
Q1 | $272K | Sell |
6,345
-1,866
| -23% | -$77K | 0.02% | 530 |
|
|
2023
Q4 | $304K | Buy |
8,211
+67
| +0.8% | +$2.4K | 0.02% | 478 |
|
|
2023
Q3 | $295K | Buy |
8,144
+1,127
| +16% | +$40K | 0.03% | 465 |
|
|
2023
Q2 | $250K | Sell |
7,017
-1,792
| -20% | -$64.3K | 0.02% | 508 |
|
|
2023
Q1 | $313K | Sell |
8,809
-904
| -9% | -$31.6K | 0.03% | 528 |
|
|
2022
Q4 | $341K | Sell |
9,713
-256
| -3% | -$8.53K | 0.03% | 458 |
|
|
2022
Q3 | $293K | Sell |
9,969
-796
| -7% | -$30.2K | 0.03% | 497 |
|
|
2022
Q2 | $586K | Sell |
10,765
-24
| -0.2% | -$1.32K | 0.06% | 338 |
|
|
2022
Q1 | $587K | Sell |
10,789
-756
| -7% | -$41.1K | 0.05% | 396 |
|
|
2021
Q4 | $636K | Buy |
11,545
+491
| +4% | +$25.5K | 0.05% | 382 |
|
|
2021
Q3 | $528K | Sell |
11,054
-339
| -3% | -$17K | 0.04% | 408 |
|
|
2021
Q2 | $567K | Buy |
11,393
+3,583
| +46% | +$172K | 0.05% | 400 |
|
|
2021
Q1 | $348K | Buy |
+7,810
| New | +$354K | 0.03% | 464 |
|
|
2020
Q4 | – | Sell |
-3,766
| Closed | -$177K | – | 784 |
|
|
2020
Q3 | $177K | Sell |
3,766
-12,108
| -76% | -$607K | 0.02% | 478 |
|
|
2020
Q2 | $809K | Buy |
15,874
+348
| +2% | +$17.9K | 0.12% | 203 |
|
|
2020
Q1 | $735K | Buy |
15,526
+777
| +5% | +$41.4K | 0.15% | 170 |
|
|
2019
Q4 | $866K | Sell |
14,749
-2,389
| -14% | -$133K | 0.12% | 199 |
|
|
2019
Q3 | $914K | Buy |
17,138
+708
| +4% | +$36.4K | 0.14% | 183 |
|
|
2019
Q2 | $822K | Buy |
16,430
+15,740
| +2,281% | +$790K | 0.13% | 190 |
|
|
2019
Q1 | $20.6K | Buy |
690
+440
| +176% | +$22K | 0.12% | 151 |
|
|
2018
Q4 | $8 | Buy |
250
+244
| +4,067% | +$12K | 0.06% | 231 |
|
|
2018
Q3 | $285 | Sell |
6
-11,271
| -100% | -$573K | 0.05% | 320 |
|
|
2018
Q2 | $568K | Buy |
11,277
+8,057
| +250% | +$406K | 0.08% | 273 |
|
|
2018
Q1 | $157K | Buy |
+3,220
| New | +$150K | 0.04% | 359 |
|
Other funds holding GSK
JEST
Centaurus Financial's GSK Position: Q2 2026 in Review
Centaurus Financial reduced its GSK (GSK) stake by 1.5% in Q2 2026, selling an estimated $1.96K and leaving 2,475 shares worth $130K. The position accounts for 0.01% of the portfolio, ranked #1014.
Centaurus Financial first reported a position in GSK in Q1 2018 and has held it in 33 quarters since. The position peaked at $914K in Q3 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Centaurus Financial held 2,475 shares of GSK worth $130K as of Q2 2026.
- Centaurus Financial sold 37 GSK shares in Q2 2026, an estimated $1.96K.
- GSK made up 0.01% of Centaurus Financial's portfolio in Q2 2026, its #1014 holding.
- Centaurus Financial first reported a position in GSK in Q1 2018 and has held it in 33 quarters since.
- Centaurus Financial's GSK position peaked at $914K in Q3 2019.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Centaurus Financial's 13F filing for Q2 2026, filed 17 Aug 2026.